EP1206463A1 - Inhibiteurs de synthase d'acide gras - Google Patents

Inhibiteurs de synthase d'acide gras

Info

Publication number
EP1206463A1
EP1206463A1 EP00957681A EP00957681A EP1206463A1 EP 1206463 A1 EP1206463 A1 EP 1206463A1 EP 00957681 A EP00957681 A EP 00957681A EP 00957681 A EP00957681 A EP 00957681A EP 1206463 A1 EP1206463 A1 EP 1206463A1
Authority
EP
European Patent Office
Prior art keywords
chloropiperonyl
mmol
scheme
aryl
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00957681A
Other languages
German (de)
English (en)
Other versions
EP1206463A4 (fr
Inventor
Siegfried B. Christensen, Iv
Robert A. Daines
Jack D. Leber
Joseph Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1206463A1 publication Critical patent/EP1206463A1/fr
Publication of EP1206463A4 publication Critical patent/EP1206463A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH. BACKGROUND OF THE INVENTION
  • the pathway for the biosynthesis of saturated fatty acids is very similar in prokaryotes and eukaryotes.
  • Vertebrates and yeasts possess type I fatty acid synthases (FASs) in which all of the enzymatic activities are encoded on one or two polypeptide chains, respectively.
  • FOSs type I fatty acid synthases
  • ACP acyl carrier protein
  • each of the reactions are catalyzed by distinct monofunctional enzymes and the ACP is a discrete protein.
  • Mycobacteria are unique in that they possess both type I and II FASs; the former is involved in basic fatty acid biosynthesis whereas the latter is involved in synthesis of complex cell envelope lipids such as mycolic acids. There therefore appears to be considerable potential for selective inhibition of the bacterial systems by broad-spectrum antibacterial agents (Jackowski, S. 1992. In Emerging Targets in Antibacterial and Antifungal Chemotherapy. Ed. J. Sutcliffe & N. Georgopapadakou. Chapman & Hall, New York; Jackowski, S. et al. (1989). J. Biol. Chem. 264, 7624-7629.)
  • the first step in the biosynthetic cycle is the condensation of malonyl-ACP with acetyl-CoA by FabH.
  • malonyl-ACP is condensed with the growing-chain acyl-ACP (FabB and FabF, synthases I and II respectively).
  • the second step in the elongation cycle is ketoester reduction by NADPH-dependent ⁇ - ketoacyl-ACP reductase (FabG).
  • Fab H is therefore a major biosynthetic enzyme which is also a key regulatory point in the overall synthetic pathway (Heath, R.J. and Rock, CO. 1996. J.Biol.Chem. 271, 1833-1836; Heath, R.J. and Rock, CO. 1996. J.Biol.Chem. 271, 10996- 11000).
  • the antibiotic thiolactomycin has broad-spectrum antibacterial activity both in vivo and in vitro and has been shown to specifically inhibit all three condensing enzymes. It is non-toxic and does not inhibit mammalian FASs (Hayashi, T. et al.,1984. J. Antibiotics 37, 1456-1461 ; Miyakawa, S. et al., 1982. J. Antibiotics 35, 41 1-419; Nawata, Y et al., 1989. Acta Cryst. C45, 978-979; Noto, T. et al, 1982. J. Antibiotics 35, 401-410; Oishi, H. et al., 1982. J. Antibiotics 35, 391-396.
  • cerulenin is a potent inhibitor of FabB & F and is bactericidal but is toxic to eukaryotes because it competes for the fatty-acyl binding site common to both FAS types (DAgnolo, G. et al.,1973. Biochim. Biophys. Acta. 326, 155-166). Extensive work with these inhibitors has proved that these enzymes are essential for viability. Little work has been carried out in Gram-positive bacteria. There is an unmet need for developing new classes of antibiotic compounds that are not subject to existing resistance mechanisms. No marketed antibiotics are targeted against fatty acid biosynthesis, therefore it is unlikely that novel antibiotics of this type would be rendered inactive by known antibiotic resistance mechanisms. Moreover, this is a potentially broad-spectrum target. Therefore, FabH inhibitors would serve to meet this unmet need.
  • This invention comprises cinnamate derivatives and pharmaceutical compositions containing these compounds and their use as FabH inhibitors that are useful as antibiotics for the treatment of Gram positive and Gram negative bacterial infections.
  • This invention further constitutes a method for treatment of a Gram negative or Gram positive bacterial infection in an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of this invention.
  • Ri is selected from the group consisting of Ci _ ⁇ rj alkyl, Cj_3 arylalkyl, Ci .3 heteroarylalkyl aryl, heteroaryl, C ⁇ _3alkyl-C3_6cycloalkyl, and C3_5cycloalkyl;
  • R2 is selected from the group consisting of O(CH2) aryl, O(CH 2 ) m heteroaryl, N(R3)(CH 2 ) m aryl, N(R 3 )(CH 2 ) m heteroaryl, N(R 4 )COaryl, N(R4)COheteroaryl, N(R4)SO2aryl and N(R4)S ⁇ 2heteroarylS ⁇ 2heteroaryl wherein the aryl and hetroaryl moieties of R1 andR2 may be optionally substituted by one or more of CH3, CF3, OCF3, OH, OCH3, NH 2 , NHCH3, N(CH 3 ) 2 , SCH3, SOCH3, SO 2 CH 3 , halogen, CO 2 H, CO CH 3 , CONH 2 , CON(CH 3 ) 2 , NHCOH, NHCOCH3, NHSO2CH3, methylenedioxy;
  • R3 is selected from the group consisting of H, C ⁇ _g alkyl, C1.3 alkyl-aryl, CO(C ⁇ _ 8 )alkyl, and COaryl;
  • R4 is selected from the group consisting of H, C i .galkyl, and C ⁇ alkyl- aryl; and m is an integer from 1 to 3; or a pharmaceutically acceptable salt thereof.
  • Ci .i oalkyl or “alkyl” means both straight and branched chains of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, ⁇ -propyl, wo-propyl, ⁇ -butyl, sec-butyl, wo-butyl, tert-butyl, «-pentyl and the like.
  • the alkyl may carry substituents such as hydroxy, carboxy, alkoxy, and the like.
  • cycloalkyl is used herein to mean cyclic rings, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean Ci-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.
  • aryl means phenyl and naphthyl and substituted aryl such as hydroxy, carboxy, halo, alkoxy, methylenedioxy, etc.
  • heteroaryl means a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, benzotriazole or benzimidazole.
  • preferred aryl substituents include halo, including chloro, fluoro, bromo and iodo, in any combination; C i .irjalkyl, Ci .irjalkoxy, aryloxy, or heteroaryloxy.
  • the compounds of this invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
  • solvates may be formed.
  • This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
  • the antibiotic compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 95% pure, particularly at least 98% pure (% are on a weight for weight basis).
  • Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 49% of a compound of the formula (I) or salt thereof.
  • Preferred compounds of the present invention include: DL-2-(6-Chloropiperonyl)-3-[4-(2,6-dichlorobenzyloxy)phenyl]propionic acid; DL-2-(6-Chloropiperonyl)-3-[4-(3,4-dichloroanilino)phenyl]propionic acid; and DL-3-[4-(3,4-Dichlorobenzyloxy)phenyl]-2-phenylpropionic acid.
  • a Knoevenagel condensation of a benzyloxybenzaldehyde 3-Scheme-4 [such as 4-(2,6-dichlorobenzyloxy)benzaldehyde] with 4-Scheme-l in a solvent (such as benzene) with catalysts (such as piperidine and acetic acid) at reflux temperature with azeotropic water removal provides 5-Scheme-l.
  • a hydride reducing reagent such as sodium borohydride
  • a solvent such as ethanol
  • This is alkylated with a benzyl halide (such as 6-chloropiperonyl chloride) using a base (such as sodium hydride) in a solvent (such as DMF) to provide 7-Scheme-l.
  • a base such as sodium hydride
  • a solvent such as DMF
  • Diethyl malonate 2-Scheme-2 is alkylated with a benzyl halide (such as 6- chloropiperonyl chloride l-Scheme-2) with a base (such as sodium hydride) in a solvent (such as DMF) and stirred (1 hours to 10 hours, preferably 3 hours).
  • a benzyl halide such as 6- chloropiperonyl chloride l-Scheme-2
  • a base such as sodium hydride
  • solvent such as DMF
  • the resulting diester is mono-saponified using a base (such as potassium hydroxide) in a solvent (such as ethanol) and stirred (4 hours to 30 hours, preferably 18 hours) to yield 3-Scheme-2.
  • a base such as potassium hydroxide
  • a solvent such as ethanol
  • a Knoevenagel condensation of 3-Scheme-2 with 4-Scheme-2 (prepared by treating the arylboronic acid with ethylene glycol with concurrent water removal) in a solvent (such as benzene) with catalysts (such as piperidine and acetic acid) at reflux temperature with azeotropic water removal provides the boronic acid 5-Scheme-2.
  • Ethyl (E)-2'-(6-chloropiperonyl)-4-(3,4-dichloroanilino)cinnamate A slurry consisting of ethyl (E)-2'-(6-chloropiperonyl)-4- dihydroxyborylcinnamate (200 mg, 0.51 mmol), 3,4-dichloroaniline (100 mg, 0.61 mmol) copper(II) acetate (122 mg, 0.61 mmol), triethylamine (430 uL, 3.1 mmol) and 4A powdered sieves (1.2 g) in methylene chloride (6 mL) was stirred open to air at room temperature for 2 h. The mixture was filtered and all volitiles removed in vacuo. purification by chromatography (silica gel, hexane/ethyl acetate) provided the title compound as a white solid (142 mg, 46%).
  • n-butyl lithium (1.53 mL of 1.5 M in hexane, 2.3 mmol) with stirring under argon. This was allowed to warm to room temperature over 15 min. then cooled to -78° C.
  • Methyl phenylacetate 300 mg, 2 mmol was added and the solution was again allowed to warm to room temperature over 15 min. then cooled to -78° C.
  • FabH was assayed in a coupled format using his-tagged S.aureus FabD, and acyl carrier protein (ACP) purchased from Sigma. Lyophilized ACP was reduced using ⁇ -mercaptoethanol in phosphate buffer. Malonyl-CoA, and FabD were added to the reduced ACP, thus generating malonyl-ACP. After the FabD reaction reached equilibrium, [ ⁇ C] acetyl-CoA and inhibitors were added, and the reaction started by the addition of FabH. TCA precipitation and filtration was used to separate [ ⁇ C] acetyl-CoA substrate from [ ⁇ C] acetoacetyl-ACP product.
  • ACP acyl carrier protein
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, and a pharmaceutically acceptable carrier.
  • the compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.
  • the antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.
  • compositions may be formulated for administration by any route, such as oral, topical or parenteral, especially oral.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • the topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • suitable conventional carriers such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
  • Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • the solution preferably contains a buffer (such as phosphate) to keep th pH in the range of about 3.5 to 7.
  • DMSO or alcoholic solvents may also be present (at concentrations such as 0.01 to 10 mL/liter) to aid solubility and penetration of the compound of Formula (I)
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • the dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions may contain from 0.1 % by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 1 to 140 mg/kg of body weight, depending on the route and frequency of administration..
  • Inhibitors of ⁇ -ketoacyl-ACP Synthase (FabH) can be administered by injection in solutions either intravenously, intramuscularly, intraperitoneally, or orally.
  • the solution preferably contains a buffer (such as phosphate) to keep the pH in the range of about 3.5 to 7.
  • DMSO or alcoholic solvents may also be present (at concentrations such as 0.01 to 10 mL/liter) to aid solubility and penetration of the ⁇ - ketoacyl-ACP Synthase (FabH) inhibitor.
  • the compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or compounds which enhance the antibacterial activity of a compound of formula (I)may be employed.
  • the antibiotic compounds of the present invention are active against a wide range of organisms including both Gram-negative organisms such as Escherichia coli and Klebsiella pneumoniae and Gram-positive organisms such as Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium, including isolates resistant to existing antibiotics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de composés comme inhibiteurs de la synthase d'acide gras FabH.
EP00957681A 1999-08-23 2000-08-23 Inhibiteurs de synthase d'acide gras Withdrawn EP1206463A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15027699P 1999-08-23 1999-08-23
US150276P 1999-08-23
PCT/US2000/023073 WO2001014362A1 (fr) 1999-08-23 2000-08-23 Inhibiteurs de synthase d'acide gras

Publications (2)

Publication Number Publication Date
EP1206463A1 true EP1206463A1 (fr) 2002-05-22
EP1206463A4 EP1206463A4 (fr) 2003-01-29

Family

ID=22533807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00957681A Withdrawn EP1206463A4 (fr) 1999-08-23 2000-08-23 Inhibiteurs de synthase d'acide gras

Country Status (4)

Country Link
EP (1) EP1206463A4 (fr)
JP (1) JP2003507467A (fr)
AU (1) AU6926500A (fr)
WO (1) WO2001014362A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335673B2 (en) 2000-08-11 2008-02-26 Kaken Pharmaceutical Co., Ltd. 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
AU2014249003A1 (en) 2013-03-13 2015-10-15 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of FASN
CN103539668B (zh) * 2013-10-22 2015-07-01 山西省化工研究所（有限公司） 合成对苯二亚甲基双丙二酸二乙酯紫外线吸收剂的工艺
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528977A (en) * 1966-12-14 1970-09-15 Colgate Palmolive Co Substituted t-aminophenylalanines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2137211B1 (fr) * 1971-05-17 1974-08-02 Bouchara Emile
IT1177966B (it) * 1984-08-14 1987-09-03 Medosan Ind Biochimi Derivati amidici dell'acido 2-(p-aminobenzil)butirrico e relativi e-steri provvisti di attivita' ipolipidemizzante
JPH04120040A (ja) * 1990-09-11 1992-04-21 Sumitomo Chem Co Ltd 光学活性なフェノール誘導体およびその製造法
JPH04124158A (ja) * 1990-09-12 1992-04-24 Sumitomo Chem Co Ltd 光学活性なフェノール誘導体およびその製造法
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528977A (en) * 1966-12-14 1970-09-15 Colgate Palmolive Co Substituted t-aminophenylalanines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0114362A1 *

Also Published As

Publication number Publication date
WO2001014362A1 (fr) 2001-03-01
EP1206463A4 (fr) 2003-01-29
AU6926500A (en) 2001-03-19
JP2003507467A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
US6469046B1 (en) Indole compounds useful for treating bacterial infections
US6608059B1 (en) Fatty acid synthase inhibitors
US6559179B1 (en) Fatty acid synthase inhibitors
US6723749B2 (en) Fatty acid synthase inhibitors
US6670388B1 (en) Fatty acid synthase inhibitors
US6498187B1 (en) Fatty acid synthase inhibitors
US20030220392A1 (en) Fatty acid synthase inhibitors
WO2001014362A1 (fr) Inhibiteurs de synthase d'acide gras
US6486192B1 (en) Indole compounds useful for treating bacterial infections
US6486211B1 (en) Indole compounds
WO2002055661A2 (fr) Inhibiteurs de la synthase des acides gras
WO2002002119A1 (fr) Inhibiteurs de la synthase d'acides gras
WO2002009651A2 (fr) Inhibiteurs de synthase d'acide gras
WO2002024197A1 (fr) Inhibiteurs des syntases d'acides gras
JP2003512452A (ja) 新規インドール化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020304

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021212

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 315/00 A

Ipc: 7C 07D 229/00 B

Ipc: 7A 61K 31/19 B

Ipc: 7C 07D 317/00 B

Ipc: 7C 07D 317/68 B

Ipc: 7C 07D 317/14 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040302